To include your compound in the COVID-19 Resource Center, submit it here.

Exanta ximelagatran: Phase III

In an international Phase III trial in 2,800 patients, Exanta met the primary endpoint of reducing

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE